Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01856933
Other study ID # 263
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 2013
Est. completion date February 2015

Study information

Verified date November 2021
Source Brown University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of Prostate Specific Membrane Antigen (PSMA ADC), as well as its safety and side effects for patients with advanced brain tumors. This study will also study how your body metabolizes (breaks down) PSMA ADC.


Description:

PSMA expression has been demonstrated in the tumor neovasculature of Glioblastoma Multiforme (GBM) by immunohistochemical staining. Strong reactivity to the antibody component of PSMA ADC was observed in the endothelial cells of new tumor blood vessels in GBM. Since the endothelial cells are located on the luminal surface of blood vessels, PSMA ADC does not need to cross the blood brain barrier to reach its target. Following binding and internalization of PSMA ADC, the cytotoxic component of PSMA ADC will be released and destroy the neovasculature that supports tumor growth. Therefore, PSMA ADC may be an active treatment for GBM. Bevacizumab, an inhibitor of angiogenesis, has been shown to be effective in improving progression-free survival as a single agent. Thus PSMA ADC, which targets tumor angiogenesis by a mechanism different from that of bevacizumab, may be a novel therapeutic modality for GBM. A phase 2 study of PSMA ADC is proposed for patients with GBM that have progressed after standard treatment that includes radiation, temozolomide and bevacizumab. A phase 1 study of PSMA ADC in prostate cancer is ongoing and a phase 2 dose level of 2.5 mg/kg IV every 3 weeks has been defined. Treatment after bevacizumab failure for patients with GBM is a major unmet medical need. If activity were demonstrated in this trial, a definitive randomized study would be proposed.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date February 2015
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Males and females Histologically confirmed GBM (Patients with gliosarcoma are also eligible) - Assessable or measurable disease by MRI - Progression after prior treatment that includes radiation, temozolomide and bevacizumab. -> 4 weeks since prior chemotherapy, bevacizumab and other systemic treatment and > 3 weeks from prior radiation. - age >18 years - Weight < 150 kg. - Karnofsky performance score > 60 - Life expectancy >12 weeks - Brain MRI within 21 days prior to registration - Laboratory results requirements - Absolute neutrophil count (ANC) = 1000/mm3. - Platelets (Plt) = 100,000/mm3 - Hemoglobin (Hgb) = 8.0 g/dL - Total bilirubin = 2.0 mg/dL - Serum alanine transferase/ Serum aspartate transaminase (ALT/AST) = 2.5x the upper limit of normal (ULN) - Serum creatinine = 2.0 mg/dL - Pancreatic Amylase (p-amylase) = the ULN - Negative serum pregnancy test for women of child-bearing potential - Stable corticosteroid dose at least 14 days prior to registration - Women of childbearing potential must have a negative pregnancy test. - Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. - Patients must not be on enzyme-inducing anti-epileptic drugs (EIAED). Patients may be on non-enzyme inducing anti-epileptic drugs (NEIAED) or may not be taking any anti-epileptic drugs. A list of AED that cause modest or no induction of hepatic metabolic enzymes will be discussed Exclusion Criteria: - Non-GBM primary invasive malignant neoplasm within the five years prior to screening except for: - keratinocyte (non-melanoma) (i.e., basal cell, squamous cell) carcinoma of the skin; or low-grade papillary superficial transitional cell carcinoma of the bladder.However, patients with stage 1 cancers not requiring cancer therapy including chemotherapy or hormone therapy, for which a lifespan of greater than 3 years without treatment is expected (such as early stage prostate cancer) may be enrolled. - Clinically significant cardiac disease (New York Heart Association Class III/ IV or severe debilitating pulmonary disease - Subjects with QTc>500 msec (either Bazzett's or Fridericia's method) - Radiation therapy, cytotoxic chemotherapy, bevacizumab or other treatment for GBM within previous three weeks - Evidence of an active infection requiring ongoing intravenous antibiotic therapy - Any toxicity = grade 2 (non-laboratory) (NCI CTCAE, Version 4.03) prior to first dose of study drug - Prior treatment with PSMA ADC or other therapies targeting PSMA, or other anti-body drug conjugate (ADC) products that contain monomethyl auristatin E (MMAE) (e.g., brentuximab vedotin, glembatumumab vedotin, ASG-5ME) - Known hypersensitivity reactions to PSMA ADC or any of its components. - Any medical condition that in the opinion of the Investigator may interfere with a subject's participation in or compliance with the study - Patients with a prior history of pancreatitis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PSMA ADC
2.5 mg/kg, IV, over 60 minutes every 3 weeks

Locations

Country Name City State
United States UT Southwestern Dallas Texas
United States Rhode Island Hospital Providence Rhode Island

Sponsors (4)

Lead Sponsor Collaborator
Heinrich Elinzano, MD Progenics Pharmaceuticals, Inc., Rhode Island Hospital, University of Texas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response Rate (Progression) for Patients With Glioblastoma That Have Progressed After Prior Treatment That Has Included Radiation, Temozolomide and Bevacizumab. The response assessment in neuro-oncology (RANO) will be used to define radiographic response.
(PD): A >25% increase in tumor area (product of two diameters) OR appearance of a new lesion/site, OR clear clinical worsening or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
3 months until progression, potentially up to 1 year
Secondary Number of Patients Who Experienced Toxicities (Adverse Events) Who Received PSMA ADC for Recurrent Glioblastoma. Please note that toxicities outlined may not all be related to the treatment regimen. at least every 3 weeks for a maximum of 30 post coming off drug, approximately 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05023551 - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma Early Phase 1
Recruiting NCT06059690 - Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells Phase 1/Phase 2
Recruiting NCT04116411 - A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients Phase 2
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Completed NCT00038493 - Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Recruiting NCT01923922 - CT Perfusion in the Prognostication of Cerebral High Grade Glioma N/A
Completed NCT01956734 - Virus DNX2401 and Temozolomide in Recurrent Glioblastoma Phase 1
Completed NCT01301430 - Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. Phase 1/Phase 2
Completed NCT01402063 - PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation Phase 2
Suspended NCT01386710 - Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Phase 1/Phase 2
Active, not recruiting NCT00995007 - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Phase 2
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2
Terminated NCT00990496 - A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) Phase 1
Completed NCT00402116 - Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Phase 1/Phase 2
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Completed NCT00504660 - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Phase 2
Recruiting NCT05366179 - Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc Phase 1